Status: Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Participants needed: 385
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Updated: Jun 23, 2026Locations: 226
Eligibility criteria
Has signs/symptoms of CD for at least 90 days prior to screening [+3]
Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, rad... [+10]